CASI Pharmaceuticals (CASI) has released an update.
CASI Pharmaceuticals has restructured its senior management to better align with its strategic business goals, eliminating the President role in favor of a new Senior Vice President position. Mr. Wei (Larry) Zhang has been appointed to this position, tasked with enhancing project coordination between the company’s China and US operations. The company’s Chairman and CEO, Dr. Wei-Wu He, expressed confidence in Zhang’s abilities to contribute to the firm’s growth and strategic direction.
For further insights into CASI stock, check out TipRanks’ Stock Analysis page.
